Elinzanetant (Lynkuet) finally getting MHRA approval to provide relief for women suffering from menopausal symptoms.
With Elinzanetant being the first non-hormonal therapy of its kind, works by modulating brain signaling to help restore normal body temperature regulation. This, in turn, reduces hot flushes and night sweats, supporting improved sleep quality and overall restfulness.
Elinzanetant’s approval follows results from the OASIS clinical trials, involving over 1,400 women aged 40–65 across multiple countries. The studies demonstrated that a daily 120 mg dose of Elinzanetant significantly reduced the frequency and severity of hot flushes and night sweats over 26–52 weeks compared with placebo.
As with all medicines, side effects may occur. A complete list will be available in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) on the MHRA website within 7 days of approval.
Anyone experiencing suspected side effects should seek advice from their healthcare professional and report them to the MHRA Yellow Card scheme or the MHRA Yellow Card app.
